EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Repurposing diacerein for the treatment of chronic wounds in recessive‐dystrophic epidermolysis bullosa patients by modulating matrix metalloproteinase‐9 expression

Sonja Dorfer iD, Michael Ablinger, Monika Wimmer, Julia I Hummel, Selma Ibrahimpašić, Anja Diem, Martin Laimer, Stefanie Gruner, Josefina Piñón Hofbauer, Christina Guttmann-Gruber, Ulrich Koller, Iris K Gratz und 3 weitere

The Journal of Dermatology · 2025-03 · 52 (3) · 423-431

DOI: 10.1111/1346-8138.17621 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Journal of Dermatology, online erschienen am 24.01.2025. Verfasst von Sonja Dorfer und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergology, EB House Austria, Research Program for Molecular Therapy of Genodermatoses, University Hospital of the Par…. Hauptthemen laut MEDLINE: Anthraquinones, Epidermolysis Bullosa Dystrophica, Matrix Metalloproteinase 9, Wound Healing. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DEBRA Alto Adige, DEBRA Austria.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recessive dystrophic epidermolysis bullosa (RDEB) is caused by mutations in COL7A1 , leading to loss or dysfunction of type‐VII collagen (C7), a protein essential for skin stability. Clinically, patients suffer from severe skin blistering, chronic or recurrent wounds, and scarring, which predispose to early onset of aggressive squamous cell carcinoma. Previous studies showed that RDEB‐keratinocytes (RDEB‐KC) express high levels of matrix‐metalloproteinase 9 (MMP‐9), a molecule known to play a crucial role in wound chronification if dysregulated. We investigated the potential of diacerein, a small molecule that interferes with the MMP‐9 regulatory pathway, to improve wound healing in a 5‐year old RDEB patient presenting with chronic, generalized skin involvement unresponsive to previous treatment approaches. Upon 4 weeks of topical therapy applied to the patient's back, parents reported a nearly complete wound closure and a significant increase in quality of life. We also provide evidence that diacerein treatment of patient keratinocytes results in a downregulation of MMP‐9 expression, accompanied by a reduction in their ability to degrade a fibrinogen matrix. These data characterize diacerein as a potential candidate for improving wound healing in RDEB through its impact on inflammatory as well as epithelial cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnthraquinonesEpidermolysis Bullosa DystrophicaMatrix Metalloproteinase 9Wound HealingChild, PreschoolHumansChronic DiseaseCollagen Type VIIDown-RegulationDrug RepositioningKeratinocytesSkin

Stichwörter der Autor:innen

RDEBdiacereinmatrix metalloproteinasewound healing

Substanzen

AnthraquinonesCOL7A1 protein, humanCollagen Type VIIdiacereinMatrix Metalloproteinase 9MMP9 protein, human

Autor:innen und Institutionen

  • Department of Dermatology and Allergology, EB House Austria, Research Program for Molecular Therapy of Genodermatoses, University Hospital of the Paracelsus Medical University Salzburg, Salzburg, Austria.
  • Department of Biosciences and Medical Biology, University of Salzburg, Salzburg, Austria.
  • Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg, Salzburg, Austria.

ORCID-Profile: Sonja Dorfer

Förderung

  • DEBRA Alto Adige
  • DEBRA Austria

Zitieren

APA

Dorfer, S., Ablinger, M., Wimmer, M., Hummel, J. I., Ibrahimpašić, S., Diem, A., Laimer, M., Gruner, S., Hofbauer, J. P., Guttmann-Gruber, C., Koller, U., Gratz, I. K., Bauer, J. W., Zauner, R., & Wally, V. (2025). Repurposing diacerein for the treatment of chronic wounds in recessive‐dystrophic epidermolysis bullosa patients by modulating matrix metalloproteinase‐9 expression. The Journal of Dermatology, 52(3), 423-431. https://doi.org/10.1111/1346-8138.17621

Vancouver

Dorfer S, Ablinger M, Wimmer M, Hummel JI, Ibrahimpašić S, Diem A, et al. Repurposing diacerein for the treatment of chronic wounds in recessive‐dystrophic epidermolysis bullosa patients by modulating matrix metalloproteinase‐9 expression. The Journal of Dermatology. 2025;52(3):423-431. doi:10.1111/1346-8138.17621

BibTeX
@article{Dorfer2025,
  author = {Dorfer, Sonja and Ablinger, Michael and Wimmer, Monika and Hummel, Julia I and Ibrahimpašić, Selma and Diem, Anja and Laimer, Martin and Gruner, Stefanie and Hofbauer, Josefina Piñón and Guttmann-Gruber, Christina and Koller, Ulrich and Gratz, Iris K and Bauer, Johann W and Zauner, Roland and Wally, Verena},
  title = {Repurposing diacerein for the treatment of chronic wounds in recessive‐dystrophic epidermolysis bullosa patients by modulating matrix metalloproteinase‐9 expression},
  journal = {The Journal of Dermatology},
  year = {2025},
  volume = {52},
  number = {3},
  pages = {423--431},
  doi = {10.1111/1346-8138.17621}
}
Kostenlos starten →